Syntex will develop Greenwich's Therafectin (amiprilose hydrochloride), which is currently in clinical trials for the treatment of rheumatoid arthritis. Syntex and Greenwich will hold co-exclusive rights to manufacture and market the drug in the U.S., while Syntex will hold exclusive marketing rights in Canada, Mexico, the Bahamas, Australia, New Zealand and Brazil. In addition to making royalty payments, Syntex will fund the remaining clinical trials.
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
No device-related close-out letters were released by the US FDA last month.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.